# Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial

> **NCT00316901** · PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 70 (estimated)

## Conditions studied

- Kidney Cancer
- Melanoma (Skin)

## Interventions

- **PROCEDURE:** computed tomography
- **PROCEDURE:** positron emission tomography
- **RADIATION:** fludeoxyglucose F 18

## Key facts

- **NCT ID:** NCT00316901
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2012-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00316901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00316901, "Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00316901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*